KOLON LIFE SCIENCE INC.

Highlights Kolon Life Science Inc.

Equities

A102940

KR7102940004

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-06-06 EDT			5-day change	1st Jan Change
21,950 ^KRW	0.00%		-1.79%	-14.59%

05-16	Kolon Life Science Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-20	Kolon Life Science Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Kolon Life Science Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-16	CI
Kolon Life Science Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
Kolon Life Science Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Kolon Life Science Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Kolon Life Science Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Kolon Life Science Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-20	CI
Kolon Life Science Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Kolon Life Science Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Juniper Biologics Pte Ltd Acquires Cell-Mediated Gene Therapy TG-C LD for Treatment of Knee Osteoarthritis	22-04-12	CI
Kolon Life Science Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-16	CI
Kolon Life Science Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-25	CI
Kolon Life Science Inc. Enters an Agreement with Kolon Life Science Inc. to License Out Invossa	18-11-19	CI
Kolon Life Science Signs Distribution Agreement with China Life Medical Center for Cell Gene Therapy Invossa	18-07-19	CI
South Korea's Ministry of Food and Drug Safety Grants Approval to Kolon Life Science to Launch Phase III Clinical Trials	17-11-24	CI
TissueGene, Inc. Announces Kolon Life Science, TissueGene's Exclusive Licensee for Asia, Including Korea, Has Received Marketing Approval for Invossa-K Inj	17-07-12	CI
Mundipharma International Ltd. Enters into Agreement with Kolon Life Science Inc	17-04-11	CI
TissueGene Licensee, Kolon Life Science, Partners with Mitsubishi Tanabe Pharma to Develop and Commercialize Invossa™	16-11-01	CI
Kolon Life Science Announces Licensing and Development Agreement with Mitsubishi Tanabe Pharma	16-10-31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer